International: +1-347-960-6455
Hypertrophic Scars Therapeutics Pipeline to Witness Remarkable Growth due to Increased Number of Pipeline Candidates by Drug Developers

According to a new research report Hypertrophic Scars Therapeutics – Pipeline Analysis 2019, Clinical Trials and Results, Patents, Designations, Collaborations, and Other Developments” published by Pharma Proff, hypertrophic scars therapeutics currently exhibits a proliferating pipeline with 15+ therapeutic candidates.

Hypertrophic Scars Therapeutics Pipeline Insights

Hypertrophic scar can be defined as a thickened and raised scar that forms at the site where skin is damaged. A hypertrophic scar is an after effect to an injury. This condition occurs when the myofibroblasts produce collagen in excess during repairing process. This can happen when an injury is infected, under an extraordinary pressure, or left to recover without stitches.

Hypertrophic scars can be effectively analyzed by physical examination as they are red and raised at the site of damaged skin and cause itchy sensations. With time, these scars tend to become flat and pale.

Application of topical silicone gel, pressure therapy, laser treatment, cryotherapy, radiation therapy, and surgical excision are some of the commonly used treatment options for hypertrophic scars. Furthermore, Kelocote spray (Advanced Bio-Technology Inc.), Kenalog-10 (Bristol-Myers Squibb Company), and SRT-100 (Sensus Healthcare) are some of the drugs approved by the U.S. Food and Drug Administration (USFDA) for the treatment of these scars.

Insights into Pipeline Segments

According to the research findings, majority of pipeline drug candidates are being developed for topical administration. It has been found that the topical route of administration is non-invasive and easy to use, and ensures high level of patient satisfaction.

Positive Clinical Trial Results are Expected to Drive Hypertrophic Scars Therapeutics Pipeline

Companies that are involved in developing therapeutics for hypertrophic scars have shown positive clinical results in various phases of drug development. For instance, in December 2014, Phio Pharmaceuticals Corp. announced positive preliminary data of phase IIa trial of RXI‑109 for the treatment of patients with hypertrophic scars. The results of the study concluded that treatment with RXI‑109 has a favorable safety and tolerability profile. The study also recorded efficacy of RXI‑109 in lowering down the prominence of hypertrophic scars.

Browse Detailed Report at:

Global Market for Hypertrophic Scars Therapeutics is Expected to Increase Statistically in the next 10 years

An analysis done for pipeline products demonstrated that RXI-109 and STP-705 are leading product candidates for the treatment of hypertrophic scars. With the approval of these candidates and rising development of other pipeline products will cater the growth of the hypertrophic scar therapeutics market in the next 10 years.

Bristol-Myers Squibb Company, Sirnaomics Inc., Phio Therapeutics Corp., Allergan plc, Sensus Healthcare, Advanced Bio-Technology Inc., OliX Pharmaceuticals Inc., SiSaf Ltd., Juventas Therapeutics Inc., HUGEL Inc., TOPADUR PHARMA AG, Phio Pharmaceuticals Corp., and Lemonex Inc. are some of the key players involved in the development of therapeutic drugs indicated for the treatment of hypertrophic scars.

Hypertrophic Scars Therapeutics Pipeline Analysis

  • By Phase
  • By Molecule Type
  • By Route of Administration
  • By Company

The report comprises detailed pipeline analysis of therapeutics being developed for the treatment of hypertrophic scars. Comprehensive insights on the pipeline phase products have been provided, with special focus on strategic developments of key players, information on drug licensing, designations, financing, and grants, technological advancements, patents, and upcoming conferences. In addition, the report highlights the winning strategies of companies involved in the hypertrophic scars therapeutics development. Detailed regulatory approval procedures in the U.S., Europe, and Japan are also provided in this report. Furthermore, the report contains competitive analysis and extensive information on monotherapies, combination therapies, targets and mechanisms of action, and drug origin with respect to hypertrophic scars.